Dr. Roger McFillin critiques pediatric antidepressant use, highlighting safety concerns, lack of efficacy, and industry bias in clinical trials and guidelines.
Key Takeaways
- No strong evidence supports antidepressants’ effectiveness in youth depression treatment.
- Antidepressants double the risk of suicidality and aggression in children and adolescents.
- Industry influence has led to biased research and misleading clinical guidelines.
- Informed consent is critical but often lacking in pediatric antidepressant prescriptions.
- Primary care providers, who prescribe most psychiatric drugs, need better education on these risks.
Summary
- Dr. Roger McFillin argues antidepressants for youth under 24 lack proven efficacy and pose significant safety risks.
- Most pediatric antidepressant trials were industry-sponsored, methodologically flawed, and selectively reported results.
- The FDA issued a black box warning in 2003-2004, expanded in 2006, highlighting increased suicidality risk in youth.
- A 2016 review found very low-quality evidence supporting antidepressant efficacy in children and adolescents.
- Many trials involved problematic placebo substitutions causing withdrawal effects, skewing results.
- There is strong evidence of adverse effects including aggression, suicide, and worsening depression.
- The American Academy of Pediatrics guidelines support antidepressant use despite FDA warnings, which Dr. McFillin calls negligent and biased.
- The AAP receives pharmaceutical funding, potentially influencing their guidelines.
- Dr. McFillin urges informed consent and dissemination of this information to primary care prescribers.
- He encourages viewers to share the video and subscribe to the Radically Genuine channel to raise awareness.











